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Abstract
An orphan disease is defined in the EU as a disorder affecting less than 1 in 2 000 individuals. The concept of
ultra-orphan has been proposed for diseases with a prevalence of less than 1:50 000. Drugs for ultra-orphan
diseases are amongst the most expensive medicines on a cost-per-patient basis. The extremely high prices have
prompted initiatives to evaluate cost-effectiveness and cost-utility in EU-member states. The objective of this
review was to evaluate the quality of cost-effectiveness and cost-utility studies on ultra-orphan drugs. We
searched 2 databases and the reference lists of relevant systematic reviews. Studies reporting on full economic
evaluations, or at least aiming at such evaluation, were eligible for inclusion. Quality was assessed with the use of
the Consensus on Health Economic Criteria (CHEC)-list. Two-hundred-fifty-one studies were identified. Of these,
16 fitted our inclusion criteria. A study on enzyme replacement and substrate reduction therapies for lysosomal
storage disorders did not perform a full economic evaluation due to the high drug costs and the lack of a measurable
effect on either clinical or health-related quality of life outcomes. Likewise, a cost-effectiveness analysis of laronidase for
mucopolysaccharidosis type 1 was considered unfeasible due to lack of clinical effectiveness data, while in the same
study a crude model was used to estimate cost-utility of enzyme replacement therapy (ERT) for Fabry disease. Three
additional studies, one on ERT for Fabry disease, one on ERT for Gaucher disease and one on eculizumab for
paroxysmal nocturnal haemoglobinuria, used an approach that was too simplistic to lead to a realistic estimate of the
incremental cost-effectiveness (ICER) or cost-utility ratio (ICUR). In all other studies (N = 11) more sophisticated
pharmacoeconomic models were used to estimate cost-effectiveness and cost-utility of the specific drug, mostly ERT
or drugs indicated for pulmonary arterial hypertension (PAH). Seven studies used a Markov-state-transition model.
Other models used were patient-level simulation models (N = 3) and decision trees (N = 1). Only 4 studies adopted a
societal perspective. All but 2 studies discounted costs and effects appropriately. Drugs for metabolic diseases
appeared to be significantly less cost-effective than drugs indicated for PAH, with ICERs ranging from €43 532 (Gaucher
disease) to €3 282 252 (Fabry disease). Quality of studies using a Markov-state-transition or patient-level simulation
model is in general good with 14–19 points on the CHEC-list. We therefore conclude that economic evaluations
of ultra-orphan drugs are feasible if pharmacoeconomic modelling is used. Considering the need for modelling of
several disease states and the small patient groups, a Markov-state-transition model seems to be most suitable
type of model. However, it should be realised that ultra-orphan drugs will usually not meet the conventional
criteria for cost-effectiveness. Nevertheless, ultra-orphan drugs are often reimbursed. Further discussion on the
use of economic evaluations and their consequences in case of ultra-orphan drugs is therefore warranted.
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Introduction
In the European Union (EU), a disease is considered ‘or-
phan’ if it is a life-threatening or seriously debilitating
disorder that affects fewer than 1 per 2 000 (or less than
0.05 %) of the population [1]. To date, 7 000 rare dis-
eases have been identified, affecting 30–40 million pa-
tients in the EU [2]. Although no legal definition of
‘ultra-orphan’ diseases has been established, this subcat-
egory was introduced by the National Institute for
Health and Care Excellence (NICE). It is suggested to be
applied to diseases with an estimated prevalence
of <1:50 000 [3]. Initially, the small consumers’ market
of orphan drugs restrained the pharmaceutical industry
from developing medicines for rare diseases. For this
reason, European legislation was introduced in 2000 to
stimulate the development of orphan drugs, following
the example of the United States who introduced the
Orphan Drug Act in 1983. This legislation implies that
the pharmaceutical industry has a right to i) obtain
protocol assistance at a reduced charge, ii) gain access to
the centralized authorization procedure, iii) get reduc-
tion of registration costs, and iv) benefit from 10 years
of market exclusivity after registration [4]. This has led
to the authorization of 124 new orphan drugs in the EU
from 2000 until 2015 by the European Medicines
Agency (EMA), of which about one-third is indicated for
an ultra-orphan disease (http://www.ema.europa.eu/
ema/). Authorization of these ultra-orphan drugs is often
based on studies in small patient groups not represent-
ing the entire patient population. Moreover, biomarkers
and intermediate endpoints are often used [5]. Because
of this, longer term effectiveness on clinically relevant
outcome measures is often unclear at the time of
authorization. If, at time of authorization, insufficient
evidence on efficacy and safety exists, the regulatory au-
thorities can register an orphan drug by approving it
‘under exceptional circumstances’. This applies to drugs
for which the applicant can demonstrate that compre-
hensive data cannot be provided (due to specific reasons
foreseen in the legislation). At the same time, costs of
orphan drugs have increased over the past years, in par-
ticular costs of ultra-orphan drugs. This rise has to do
with the rapid technical advances including unravelling
of molecular mechanisms that underlie some diseases
and require a more personalised approach [6]. About
250 new rare diseases are described annually [7]. For
member states to make decisions on reimbursement, it
is important to gain a better insight into the balance be-
tween expenses and health gains for a specific drug in
order to determine the ‘value for money’ for orphan
drugs. Consequently, economic evaluations play an im-
portant role in current decision making about the reim-
bursement of drugs. In some countries in the EU,
reimbursement of drugs depends on the incremental
costs per quality-adjusted life year (QALY). In England
and Wales, incremental costs exceeding £20 000 to £30
000 per QALY gained are in principle not reimbursed
[8–10]. Conversely, other countries in the EU recom-
mend against any pre-set threshold. It is, however, a sci-
entific challenge to evaluate the cost-effectiveness or
cost-utility of orphan drugs. With this review we aim to
assess the economic evaluations ultra-orphan drugs mar-
keted in the EU that have been performed so far with
specific focus on the methods used and the quality of
the studies.
Methods
The EMA created the ‘List of medicinal products for
rare diseases in Europe’ (http://ec.europa.eu/health/doc-
uments/community-register/html/index_en.htm), which
describes orphan medicinal products (OMPs) in Europe
with European orphan designation and marketing
authorization. We used this list, which was updated in
April 2015, to identify all OMPs in Europe. Subse-
quently, www.orpha.net was searched to select those
drugs that were developed to treat ultra-orphan diseases
(prevalence < 1:50 000).
For each OMP included in this study, we conducted a
literature search in the databases of MEDLINE and
EMBASE (both via OvidSP) for economic evaluations
published prior to April 2015. Key terms used included
the disease indication, the drug’s generic name and EU
brand name, and the terms cost-benefit, cost-effectiveness,
health economics, pharmaco-economics, economic evalu-
ation and quality-adjusted life years, including alternative
notations. Additional reports were identified by hand
searching the reference lists in the retrieved papers. For
each literature search, one author (YS) read the titles and
abstracts of all identified studies. If considered relevant, full
text was read and analysed. Papers that met the following
inclusion criteria were included: I) reporting on an original
cost-effectiveness or cost-utility analysis, or at least aiming
at such analysis, of an orphan drug for its approved orphan
indication, II) orphan drug is marketed in the EU and is in-
dicated for a condition with a prevalence of <1:50 000
(ultra-orphan drug), and III) article is published in the Eng-
lish language. OMPs withdrawn from the EU market or
discontinued from the community register of orphan me-
dicinal products (at the end of the 10-year period of market
exclusivity) were also included. Studies in which data on
costs and/or utilization were collected but not related to a
measure of benefit were excluded. To convert different
currencies used in the included studies, we used a currency
converter (May 2015).
We used the 19-item Consensus on Health Economic
Criteria (CHEC)-list to assess the quality of economic
evaluations (see Fig. 1) [11]. The CHEC-list has been de-
veloped using a Delphi method and focuses on the
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methodological quality of economic evaluation aspects.
It was developed for systematic reviews of full economic
evaluations based on effectiveness studies (cohort stud-
ies, case–control studies, randomized controlled trials)
and is recommended by the Cochrane Handbook for
Systematic Reviews of Interventions [12]. The CHEC




We identified 32 ultra-orphan drugs from the EMA and
Orphanet website. The cost-utility study for type 1
Gaucher disease compares ERT (imiglucerase [Cere-
zyme®] and velaglucerase alfa [Vpriv®]) with standard
medical care [13]. Although imiglucerase is not regis-
tered as an (ultra) orphan drug due to the fact that the
EU orphan legislation was installed at a later stage, we
decided to include this study in our review since
Gaucher is considered to be an ultra-orphan disease.
The same applies to the study by Beutler et al., which
compares alglucerase (Ceredase®) for Gaucher disease to
standard of care [14]. The literature search resulted in
251 articles, of which 16 met our inclusion criteria (see
Fig. 2). The majority of the studies considered treat-
ments of lysosomal storage disorders (LSDs) and pul-
monary arterial hypertension (PAH). Two of the 16
articles reported on more than 1 ultra-orphan drug
resulting in 19 economic evaluations in total (see
Table 1). The table summarizes the methods used, com-
parators, base-case incremental cost-effectiveness ratios
(ICERs)/cost-utility ratios (ICURs), and CHEC-list sum
scores. To estimate the ICER/ICUR of ultra-orphan
drugs marketed for LSDs (alglucosidase alfa [Myozyme®],
agalsidase alfa [Replagal®], algasidase beta [Fabrazyme®],
alglucerase, imiglucerase, velaglucerase alfa and mercapta-
mine [Procysbi®]) and for paroxysmal nocturnal haemo-
globinuria (eculizumab [Soliris®]), these drugs have been
compared to standard medical care, while ultra-orphan
drugs for PAH (sildenafil [Revatio®], iloprost [Ventavis®],
bosentan [Tracleer®] and ambrisentan [Volibris®]) have
been compared with each other. Agalsidase alfa, agalsidase
beta, laronidase, sildenafil, iloprost and bosentan were ap-
proved under exceptional circumstances. The majority of
the studies included were conducted in the USA [14–18],
followed by the UK [19–23], and the Netherlands [13, 24,
25]. The remaining studies have been conducted in Spain
[26], Australia [27] and Canada 28].
Economic models
A study on enzyme replacement and substrate reduction
therapies for LSDs did not conduct a full economic
evaluation since a cost-effectiveness or cost-utility ana-
lysis was considered unfeasible due to the high drug
costs and the lack of a measurable effect on either clin-
ical or health-related quality of life outcomes [22]. In
spite of this, the authors calculated that 3.6–17.9 dis-
counted QALYs would need to be generated for each
year of being treated in order for them to be cost-
effective. Likewise, a cost-effectiveness analysis of laroni-
dase [Aldurazyme®] for mucopolysaccharidosis type 1
was not performed as a consequence of limited evidence
Fig. 1 Consensus on Health Economic Criteria (CHEC) list
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of effectiveness [21]. In the same study, a crude decision
model was used to estimate cost-utility of agalsidase alfa
and beta for Fabry disease. A perfect drug scenario was
assumed (i.e., treatment with agalsidase alfa or beta was
assumed to restore patients to full health), which un-
doubtedly led to an underestimation of the ICUR (€351
622 per QALY). The same holds true for another study
on enzyme replacement therapy (ERT) for Fabry disease
[16]. This study roughly estimated health gains based on
only 2 studies, of which 1 reported utilities of Fabry pa-
tients in the pre-ERT era and the other used data from
the Fabry Outcome Survey (FOS, a Shire sponsored
post-marketing drug registry) 10 years later. It is known,
however, that the availability of ERT prompted aware-
ness programs and screening studies which ultimately
led to an expansion of the disease’s phenotype. Conse-
quently, the FOS cohort consists of patients who have
on average a milder disease course than the patients in
the pre-ERT study, making it incorrect to ascribe the
higher utility scores to the effect of ERT. The reported
80 % probability that ERT has a positive net benefit at a
willingness-to-pay of €266 520 per QALY is therefore an
overestimation. Cost-utility of alglucerase for Gaucher
disease was roughly estimated without using a compre-
hensive economic model. The authors assumed the best
effect a drug can have (immediate death versus survival
with perfect quality of life) which certainly led to an
underestimation of the ICUR (€43 532–€130 595 per
QALY depending on the dose used) [14]. Finally, Con-
nock et al. conducted three crude economic evaluations.
Under the assumptions that eculizumab returns survival
to normal, the ICER varied from €697 500–€1 953
000per life year gained [23]. In all 4 studies an imprecise
estimate of costs was made [14, 16, 21, 23].
The remaining 11 studies used more sophisticated
pharmacoeconomic models to evaluate costs and ef-
fects of a certain treatment, of which 7 used a Markov-
state-transition model [13, 15, 18, 19, 25, 26, 28].
Other models used were patient-level simulation
models (N = 3) [20, 24, 27] and decision trees (N = 1)
[17]. In only 1 study the scientific basis of the model
was explained [20]. In this study, a patient-level simu-
lation model was used because the authors found it
more computationally efficient and it removed the
need for establishing arbitrary durations for the time
cycles as required by a Markov model. In general,
pharmacoeconomic models use data from different
sources such as literature, own patient cohorts and
clinical experience, and are therefore able to give more
precise estimates than the studies mentioned above.
Fig. 2 Study flow diagram
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Table 1 Results of included studies
Drug Indication Prevalence Comparator(s) Economic model Base-case results per
QALY, discounted
Study characteristics and limitations CHEC
score
Reference
ERT/SRT LSDs <1: 50 000 soc No cost-effectiveness analyses were undertaken owing to the high drug costs and the lack of measurable
effect on either clinical or health-related quality of life outcomes. Combined with the current annual price of
the different ERTs, between 3.6 and 17.9 discounted QALYs would need to be generated for each year of being














€3 282 252 Eleven Markov states were defined, including no
symptoms, one or multiple complications and
death, with a 1-year cycle period and a time
horizon of 70 years. TPs, utilities and costs (both
direct and indirect) were derived from retrospective
and prospective follow-up data of the Dutch cohort.
Utilities and costs were assumed to be equal in
both arms as long as patients are in the same






Fabry disease 0.22: 100
000
soc Not specified €351 622b Limited information reported in the literature
precluded the development of a comprehensive
model. The decision model considered a birth
cohort of male patients. Survival and utilities for
untreated patients were estimated from literature.
ERT was assumed to restore patients to full health







Fabry disease 0.22: 100
000
soc Not specified 80 % probability that ERT
has a positive net benefit
at a willingness to pay per
QALY of €266 520b
Utilities were estimated on the basis of 2 studies.
Costs were roughly estimated without using
references. Bootstrapping was used to obtain ICER
distributions. Results were plotted in a cost-
effectiveness acceptability-curve. Primary objective
of the study was not to calculate the ICER but to






Gaucher disease 1: 100 000 soc Markov-state-
transition model
€432 540 Eight Markov states were defined, including no
symptoms, one or multiple complications and death,
with a 1-year cycle period and a time horizon of
85 years. TPs, utilities and costs (both direct and
indirect) were derived from retrospective and
prospective follow-up data of the Dutch cohort.
Utilities and costs were assumed to be equal in
both arms as long as patients are in the same





Gaucher disease 1: 100 000 soc Not specified €43 532b (2.3U/kg three
times weekly)
Estimate of ICERs for 3 drug dosing regimens was
based on the assumption that alglucerase results in



























€1 043 868 Survival in both treatment arms was estimated on
the basis of international studies, literature and their
own patient cohort. Utilities and costs were derived
from 6 and 12 patients resp., and were assumed to












England: €326 791b Two Markov states were defined: alive-symptomatic
and dead, with a 1-year cycle and a time horizon
of 20 years. Survival rate (75 vs 8 %) and costs were
derived from literature and historic databases. It was
assumed that ERT would result in higher utilities.
Only direct costs were considered. Costs and QALYs










1: 500 000 soc Markov-state-
transition model
€1 620 256b Six different consequences from PNH or treatment
were modelled. Patients may have more than 1
complication at the same time, resulting in a total
of 47 disease states. Analysis was conducted for 6
patient strata to account for differences in
thrombosis risk and transfusion requirements. TPs
for both arms were estimated on the basis of
cohort studies and clinical trials. Utilities were








1: 500 000 soc Not specified 1) €358 655 (haemoglobin)
€474 998 (LDH)
Due to the lack of reliable quantitative information
about costs and benefit of eculilzumab, a fully
informed estimation of cost-effectiveness was not
feasible. Instead, 3 preliminary analyses were
conducted to estimate the costs per: 1) patient
with stabilised of haemoglobin and normalised
LDH, 2) LYG under the assumption that eculizumab
returns survival to normal, and 3) LYG based on
reduced mortality rates from thrombosis.
9 Connock
[28]
2) €697 500 - €1 953
000/LYG




Cystinosis <1: 50 000 soc Decision tree Dominant; cysteamine is
more effective and less
expensive
Drug studied is cysteamine (Cystagon), which is
the ‘reference drug’ for mercaptamine, i.e., both
drugs are equal. Time to first renal failure was
estimated to be 10 years for untreated and 15
years for treated patients based on literature. After
first renal failure all patients were assumed to follow
the same disease course. Only direct costs were
considered. Costs were discounted, outcomes
were not. Hence life expectancy increases by 5
years while costs for dialysis and transplants are















more effective and less
expensive
Five states were defined (WHO functional classes
and death), with a 3-month cycle period and a
time horizon of 1 year. The model was based on
100 hypothetical patients with a gender and disease
severity distribution based on previous studies. TPs

















Table 1 Results of included studies (Continued)
bosentan and estimated for the other drugs after
adjustment for improvement in 6MWT. Reported
utility values for each functional class were used,
adjusted for route of administration. Only direct
costs were considered.




€1 228 055b See description above for Garin [15] 15
(2)a
Garin [15]
epoprostenol €1 016 649b
Iloprost
(Ventavis)





more effective and less
expensive
Five Markov states were defined representing the
WHO functional classes and death, with a 3-month
cycle period and a time horizon of 3 year. Treatment
changes were allowed if patient status worsened. The
model was based on 100 hypothetical patients with
functional class III. TPs were based on 6MWT results ob-
tained from clinical trials, utilities from the literature.
Only direct costs were considered. All parameters were












more effective and less
expensive
Time to progression functional class III to IV and utilities
were estimated on the basis of international studies
and literature. Life expectancy was assumed to be
independent of the initial treatment. Time spent in the
most severe disease state (with higher costs due to
continuous treatment with prostaglandins in this state,
and lower utility) is thus the only varying outcome
parameter between the 2 treatment arms. Only direct
costs were considered. 10,000 patients were simulated
and replicated. For each patient a discrete event
simulation approach was used in which the simulated














more effective and less
expensive
Five Markov states were defined representing the WHO
functional classes and death, with a 3-month cycle
period and a time horizon of 1 year. The model was
based on 100 hypothetical patients. TPs were based on
3-months transitions reported for bosentan and
estimated for the other drugs after adjustment for
improvement in 6MWT. Utilities were estimated by a










€40 137 / LYGb Mortality rate in both treatment arms was estimated on
the basis of international studies and literature. The key
assumption was that bosentan increases life
expectancy. Only direct costs were considered. 5,000
patients were simulated and replicated. At 6-months
intervals the patient progressed through one or more
health states (bosentan, conventional therapy or death)











































more effective and less
expensive
See description above for Garin [15] 15
(2)a
Garin [15]
bosentan Equal; no difference in
effectiveness and costs
treprostinil €65 282b
sildenafil Dominated; ambrisentan is
equally effective but more
expensive
sitaxentan €2 621b
ERT enzyme replacement therapy, SRT substrate reduction therapy, LSD lysosomal storage disorder, MPS mucopolysaccharidosis, PAH pulmonary arterial hypertension, ICER incremental cost-effectiveness ratio, QALY
quality adjusted life year, LYG life year gained, soc standard of care, TP transition probability, 6MWT 6-minute walk test
a The number of items that were not applicable from the CHEC-List appears in parentheses. For example, discounting is not applicable for studies with a follow up of 1 year or less















Quality scoring of studies that conducted a cost-
effectiveness or cost-utility analysis varied from 7 to 19 out
of 19 points on the CHEC-list, with studies using a very
simple model having lower scores (7–13) [14, 16, 21, 23]
than studies using a Markov-state-transition or patient-
level simulation model (14–19) [13, 15, 18–20, 24–28].
The study that used a decision tree scored 15 points [17].
Data on costs and effects were mostly obtained from
literature, hospital databases, and health and labour
questionnaires. The studies that used a patient-level
simulation model restricted events to clinical deterior-
ation and/or death [20, 24, 27], while Markov-state-
transition models used up to 47 disease states to de-
scribe the course of the disease under study [28]. All
studies measured outcomes in QALYs (cost-utility ana-
lyses), except for 2 studies in which costs per life year
gained was calculated [23, 27]. Four studies considered a
societal perspective [13, 17, 24, 25], while the other stud-
ies considered only direct medical costs (i.e., a health
care perspective) [14–16, 18–21, 23, 26–28]. In all but 2
[16, 17] studies costs and effects were discounted appro-
priately. The studies by Highland and Garin did not re-
quire discounting as the time horizon was 1 year [15,
18]. In most studies the ICER/ICUR was calculated. If a
drug is both clinically superior and less expensive, the
drug under study is referred to as a ‘dominant’ drug.
The opposite is a ‘dominated’ drug, which applies to
ambrisentan in the study by Garin et al. [15]. In both
cases of dominancy, the ICER would have reached a
negative value and is usually not calculated. Thirteen
studies applied a sensitivity analysis [13, 15–21, 24–28].
Eight studies discussed the issue of generalizability for
application in a different context [13, 15–19, 21, 27].
CHEC-list scores of individual studies are shown in
Additional file 1.
Incremental cost-effectiveness/cost-utility ratios
The ICERs and ICURs of individual ultra-orphan drugs
are depicted in Table 1. In general, drugs for metabolic
diseases appeared to be significantly less cost-effective
than drugs indicated for PAH. This can be explained by
the lower costs of drugs for PAH, and the short life ex-
pectancy (median survival of 2.8 years) of PAH patients
if they remain untreated. Effective treatment options can
thus result in a substantial number of life years gained,
in contrast to the drugs for the slowly progressive,
chronic metabolic diseases.
Remarkable differences are observed when comparing
the ICURs from different economic evaluations in Fabry
disease (€351 622 to €3 282 252 per QALY) [21, 25],
Pompe disease (€153 405 to €1 043 868 per QALY) [19,
24], and Gaucher disease (€43 532 to €432 540 per
QALY) [13, 14]. These differences can be attributed to
the assumptions made; studies assuming survival with
perfect quality of life [14, 21], or a huge increase in sur-
vival rate [19] upon therapy result in lower but less real-
istic ICURs.
Discussion
We conducted a systematic review to identify cost-
effectiveness and cost-utility studies for ultra-orphan
drugs marketed in the EU and applied the CHEC-list to
assess the quality of studies included. The challenges to
perform adequate economic evaluations in the very
small populations of ultra-orphan drugs are expected to
be similar to the challenges in the broader group of or-
phan drugs and for drugs that are used for rare indica-
tions but have not received orphan drug designation.
Only a limited number (N = 16) of studies on the cost-
effectiveness or cost-utility of ultra-orphan drugs have
been published, most of which were performed in the
USA, the UK and the Netherlands. The large representa-
tion of studies from the UK and the Netherlands can be
explained by the obligation to perform post-marketing
economic evaluations in order to gain reimbursement.
In the USA health technology assessments are not sys-
tematically conducted, but to an increasing extent or-
phans are part of the debate on pricing and cost-
effectiveness [29].
Five of the 16 studies did not succeed to perform a
real economic evaluation, or used an approach that was
too simplistic to lead to a realistic estimate of the ICER/
ICUR [14, 16, 21–23]. The latter either assumed the
maximum possible benefit from therapy (immediate
death in case of no treatment versus survival with per-
fect quality of life with treatment) [14, 21, 23], or based
their estimate of effectiveness on only a very limited
number of studies which probably led to an overesti-
mation of treatment effect [16]. These studies highlight
the fact that economic evaluations of ultra-orphan drugs
are faced with many difficulties and limitations. The low
number of patients and often slowly progressive, chronic
character of the disease make a randomized clinical trial
to estimate cost-effectiveness or cost-utility unfeasible.
Pharmacoeconomic models using data from different
sources such as literature, own patient cohorts and clin-
ical experience are therefore more suitable [30]. Indeed,
the majority of studies (N = 11) used models to estimate
the cost-effectiveness or cost-utility ratio, including
Markov-state-transition models in 7 studies, patient-
level simulation models in 3 studies, and a decision tree
in 1 study. A decision tree is the most simple model of
disease progression. This type of model is primarily use-
ful for short time horizon decisions where the likelihood
of an event's occurrence is constant over time. It is in
general not suitable for slowly progressive, chronic dis-
eases although it has been used in the assessment of
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mercaptamin for the treatment of cystinosis [17]. The
authors assumed that treatment would delay renal fail-
ure for 5 years. After renal failure all patients were as-
sumed to follow the same disease course with dialysis
and transplants, irrespective of previous treatment. Such
a simplification of the disease course can be analysed
with a decision tree, but the modelling choice for a
chronic disease usually comes down to a choice between
a cohort-level modelling approach such as a Markov-
state-transition model, and a patient-level simulation
model such as discrete event simulation (DES), which
both allow for a more detailed representation of the dis-
ease course.
In patient-level simulation models, each patient is rep-
resented individually and the final outcomes are calcu-
lated by aggregating over all individuals [31]. This type
of model has greater flexibility and allows for a better
representation of heterogeneous patient cohorts than a
Markov-state-transition model, since it allows for irregu-
lar time intervals between events. Also, the possibility to
make the time to future events dependent on patient at-
tributes including their history of previous events may
result in a better reflection of the actual disease course.
However, this type of model is in general more complex
and needs more patient data to be able to reliably esti-
mate specific effects and interactions of symptoms and
complications on the progression of the disease. Kanters
et al. used such a model to calculate costs and effects of
alglucosidase alfa for the treatment of the infantile form
of Pompe disease [24]. Only survival was modeled as
event, making it a relatively simple model without the
need for large patient numbers. Cost-effectiveness of
bosentan has also been studied with patient-level simula-
tion models [20, 27]. Again, only a limited number of
events (clinical deterioration and/or death) were mod-
elled. All 3 studies scored between 14 and 17 points.
The question is whether a model with a very limited
number of events accurately reflects the actual disease
course. Complications that arise during the course of the
disease were not taken into account while they probably
result in a decrease in quality of life and an increase in
costs. The model would become more complicated if
these events were to be incorporated. The very small
patient numbers in the case of ultra-orphan diseases
may then limit the use of a patient-level simulation
model, since it will be hard to gather sufficient infor-
mation for reliable estimates of effects and interac-
tions of symptoms and complications. Therefore,
economic evaluations of ultra-orphan drugs will often
use a cohort-simulation model, more specifically a
Markov-state-transition model. This type of model
has been used to estimate costs and effects of ERT
for Gaucher, Fabry and Pompe disease [13, 19, 25], as
well as drugs indicated for paroxysmal nocturnal
haemoglobinuria [28] and PAH [15, 18, 26]. All stud-
ies scored between 14 and 19 points. In contrast to
the patient-level simulation model, the Markov model
represents the study population as a homogeneous
cohort. It is particularly suitable to reflect the con-
tinuous risk of a disease over a long time period [30].
However, the suitability might be limited by the Mar-
kovian assumption of ‘no memory’, which means that
the probability of transitioning from one state to the
other entirely depends on the state the patient is in,
regardless of the states the patient passed through the
past.
In summary, the choice of which type of economic
model to use is dependent on the type of disease that is
described, the amount of data available, but also on the
time and experience of the researcher. A Markov-state-
transition model seems to be most suitable model for
economic evaluations of ultra-orphan drugs considering
the need for the incorporation of several disease states
and the small patient groups. It should be noted here
that we found a wide range of ICURs for the same drug
even if the same type of model was used. This is at least
partly caused by the many assumptions that had to be
made due to limited data sets. To be able to build a
model that comes as close as possible to the actual
course of the disease under study, and to reduce as
much as possible the uncertainty of the ICER/ICUR, it is
of utmost importance to gather sufficient data. A crucial
step in generating data is to establish disease-specific
registries which include longitudinal data on all affected
patients in the EU. Ideally, registries would start before
drugs are marketed, to be able to generate data about
the natural history of the disease. For this purpose, EU
countries need to work in close collaboration. Existence
of reliable data on the natural course and effectiveness
of therapy enables researchers to conduct sound eco-
nomic evaluations.
On the other hand, it has been argued that cost-
effectiveness or cost-utility studies are inappropriate in
the case of (ultra) orphan drugs since conventional cri-
teria for cost-effectiveness will never be met. Indeed,
considering studies using either a Markov-state-transition
or patient-level simulation model, ICURs for different
types of ERT ranged from €432 540 (Gaucher disease) to
€3 282 252 (Fabry disease). Wyatt et al. calculated the
number of QALYs to be generated each year in order for
different types of ERT to be cost-effective which resulted
in the impossible amount of 3.6-17.9 QALYs [22]. Conse-
quently, most ultra-orphan drugs are not ‘cost-effective’ if
standard health technology assessment procedures were
to be applied to them, which was already stated in a previ-
ous paper by Drummond et al. [32]. It is highly unlikely
that the ICUR could be decreased by the orders of magni-
tude required to make ultra-orphan drugs cost-efficient by
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current standards in the future. Although there is no clear
consensus on what constitutes an acceptable cost-utility
ratio, in the Netherlands a value of €80 000 per QALY for
illnesses associated with a considerable burden has been
suggested. However, so far, no drugs have been withdrawn
from being reimbursed because of their unfavourable
ICUR in the Netherlands. The National Institute for
Health and Clinical Excellence (NICE) in England and
Wales uses a threshold ICUR of £20 000 - £30 000 per
QALY for non-orphan drugs [33]. The value of ultra-
orphan drugs is assessed in a ‘Highly specialised tech-
nology (HST)’ programme, which is similar to the
Single Technology Appraisal process [34]. The ICUR
of £20 000 - £30 000 per QALY is not strictly ad-
hered to when evaluating orphan drugs, and greater
emphasis is applied to other factors such as ethics
and lack of alternative treatments. In other countries
in the EU (such as Ireland) there is no threshold
ICUR value [35]. The lack of consensus on the
threshold of the ICUR and absence of consequences
for reimbursement in some countries may imply that
cost-utility is not the only principle that has to be
taken into account when assessing the value of or-
phan drugs. From a societal perspective, other (eth-
ical) considerations may matter, such as the rarity
and seriousness of the disease, the availability of alter-
native therapies and the cost to the patient if the
drug would not be reimbursed [36]. These may be
reasons to accept higher costs per QALY. Possibilities
to deal with this are to apply variable cost-utility
thresholds with a higher threshold for orphan drugs,
or to value the health gain in a patient with a rare
disease with a higher weight [5]. It is questionable,
however, whether the QALY in itself is a suitable out-
come measure in the case of ultra-orphan diseases. In
most studies the EQ-5D (EuroQoL five dimensions)
quality of life questionnaire is used to determine
health status. Each observed health score profile on
this questionnaire can be converted to a utility score
ranging from - 0.594 (i.e., serious health problems
with mobility, self-care, usual activities, pain/discom-
fort, and mood) to 1 (i.e., no problems at all). Pa-
tients with a slowly progressive, chronic disease will
not be cured from one day to the other. In other
words, the utility score will mostly not increase to
perfect quality of life upon therapy. Instead, patients
may feel less tired and better capable of working
which is less well represented in the EQ-5D question-
naire. Consequently, the use of the QALY in its
current form for the assessment of cost-utility of
ultra-orphan drugs has been constantly discussed (see
for example: http://www.rarediseaseblogs.net/author/
cees-smit/). Others have argued that the QALY meas-
ure is even invalid [37]. Beresniak et al. asked more
than 1300 subjects to express their preferences re-
garding combinations of different health states and
time durations, which were subsequently compared to
the results of the QALY formula (quality of life x
number of life-years). They showed that observed and
calculated utility values were significantly different.
This might explain why costs/QALY estimates vary
greatly. The authors argued that other approaches for
health care decisions should be considered. Indeed,
the costs/QALY approach has been rejected by the
USA and Germany for ethical and methodological
reasons [38, 39]. However, to remove an imperfect
measure without replacing it with another might be
not advisable [40].
Aside from using more suitable, representative ways to
determine health status, bringing down costs would also
lead to more acceptable ICERs/ICURs. The extremely
high prices charged for new orphan drugs may cause an
unsustainable pricing market that threatens the health
care structure [41].
Conclusions
Altogether, economic evaluations of ultra-orphan drugs
are feasible if pharmacoeconomic modelling is used. The
most suitable type of model seems to be a Markov-state-
transition model. It should be realised, however, that
most ultra-orphan drugs will not meet conventional cri-
teria for cost-effectiveness. Still, ultra-orphan drugs are
often reimbursed. Further discussion on the application
of economic evaluations and their consequences in case
of ultra-orphan drugs is therefore called for. The chal-
lenges described in this study may also apply to the
broader group of (non-ultra) orphan drugs. However,
this needs further study.
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